Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $60.8 million.

  • Gyre Therapeutics' Non-Current Assets fell 1366.3% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $244.1 million, marking a year-over-year decrease of 480.22%. This contributed to the annual value of $60.6 million for FY2024, which is 219.49% up from last year.
  • Per Gyre Therapeutics' latest filing, its Non-Current Assets stood at $60.8 million for Q3 2025, which was down 1366.3% from $61.4 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Non-Current Assets high stood at $70.4 million for Q3 2024, and its period low was $773000.0 during Q3 2022.
  • In the last 5 years, Gyre Therapeutics' Non-Current Assets had a median value of $5.0 million in 2021 and averaged $30.1 million.
  • Per our database at Business Quant, Gyre Therapeutics' Non-Current Assets plummeted by 8309.64% in 2022 and then skyrocketed by 135759.52% in 2024.
  • Gyre Therapeutics' Non-Current Assets (Quarter) stood at $4.2 million in 2021, then skyrocketed by 738.51% to $35.1 million in 2022, then soared by 69.0% to $59.3 million in 2023, then grew by 2.19% to $60.6 million in 2024, then increased by 0.31% to $60.8 million in 2025.
  • Its last three reported values are $60.8 million in Q3 2025, $61.4 million for Q2 2025, and $61.3 million during Q1 2025.